Investors wait Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s quarterly earnings on March, 14., according to Faxor. Analysts have anticipation on stock’s EPS of $-0.10. That’s down 600.00 % from last year’s $0.02 EPS. Last quarter $-0.15 EPS was reported. Analysts predicts -33.33 % EPS growth this quarter. BCLI hit $3.88 during the last trading session after $0.02 change.Currently Brainstorm Cell Therapeutics Inc. is downtrending after 25.37% change in last March 4, 2018. BCLI has also 4,764 shares volume. BCLI underperformed the S&P 500 by 25.37%.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others.The firm is valued at $80.34 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd.Currently it has negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

For more Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news published recently go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial – GlobeNewswire” published on December 26, 2018, “BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences – GlobeNewswire” on November 07, 2018, “BrainStorm Appoints Arturo Araya as Chief Commercial Officer – GlobeNewswire” with a publish date: September 04, 2018, “Health Care Sector Update for 12/17/2018: PTI, EVFM, BCLI, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” and the last “BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis – GlobeNewswire” with publication date: November 19, 2018.